Teacher Retirement System of Texas Acquires Shares of 20,264 Dynavax Technologies Co. (DVAX)

Teacher Retirement System of Texas acquired a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 20,264 shares of the biopharmaceutical company’s stock, valued at approximately $379,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada raised its stake in shares of Dynavax Technologies by 17.0% during the second quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock valued at $198,000 after purchasing an additional 2,975 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Dynavax Technologies by 13.3% during the second quarter. Parametric Portfolio Associates LLC now owns 30,755 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 3,604 shares during the period. Voya Investment Management LLC raised its stake in shares of Dynavax Technologies by 26.3% during the second quarter. Voya Investment Management LLC now owns 21,403 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 4,462 shares during the period. Legal & General Group Plc increased its stake in shares of Dynavax Technologies by 36.1% in the third quarter. Legal & General Group Plc now owns 17,013 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 4,512 shares during the last quarter. Finally, Vident Investment Advisory LLC increased its stake in shares of Dynavax Technologies by 3.1% in the third quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 4,553 shares during the last quarter. Institutional investors own 71.22% of the company’s stock.

How to Become a New Pot Stock Millionaire

DVAX has been the subject of a number of research analyst reports. ValuEngine lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Zacks Investment Research lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. JPMorgan Chase & Co. lowered shares of Dynavax Technologies from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $31.00 to $25.00 in a research note on Wednesday, February 14th. Finally, Cowen restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research note on Wednesday, February 21st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Dynavax Technologies currently has a consensus rating of “Hold” and a consensus price target of $24.67.

Shares of Dynavax Technologies Co. (DVAX) opened at $16.70 on Tuesday. Dynavax Technologies Co. has a 12 month low of $5.00 and a 12 month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.32). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.53 million. Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%. sell-side analysts predict that Dynavax Technologies Co. will post -1.91 earnings per share for the current fiscal year.

In other Dynavax Technologies news, VP David Louis Johnson sold 3,092 shares of Dynavax Technologies stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the completion of the transaction, the vice president now owns 7,780 shares of the company’s stock, valued at $144,708. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider David F. Novack sold 2,121 shares of Dynavax Technologies stock in a transaction on Friday, March 9th. The stock was sold at an average price of $17.97, for a total transaction of $38,114.37. Following the completion of the transaction, the insider now directly owns 77,192 shares of the company’s stock, valued at approximately $1,387,140.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,536 shares of company stock valued at $923,418. 2.90% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.thestockobserver.com/2018/03/20/teacher-retirement-system-of-texas-acquires-shares-of-20264-dynavax-technologies-co-dvax.html.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply